T1	intervention 27 65	neoadjuvant chemotherapy +/- letrozole
T2	outcome 1118 1150	clinical complete response rates
T3	iv-bin-percent 1156 1161	27.6%
T4	cv-bin-percent 1166 1171	10.2%
T5	outcome 989 1023	Pathologic complete response rates
T6	iv-bin-percent 1029 1034	25.5%
T7	cv-bin-percent 1039 1044	10.2%
T8	total-participants 364 383	One hundred and one
T9	age 410 421	50-83 years
T10	eligibility 422 517	with pathologically proven locally advanced (clinical stage T3, T4 and/or N2, N3) breast cancer
T12	control-participants 601 603	51
T13	intervention-participants 682 684	50
T14	outcome 1433 1439	nausea
T15	outcome 1441 1449	vomiting
T16	outcome 1451 1474	bone marrow suppression
T17	outcome 1480 1489	mucositis
T18	outcome 1523 1532	hot flush
T11	control 564 595	chemotherapy alone (control arm
